HRP20191396T1 - Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze - Google Patents

Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze Download PDF

Info

Publication number
HRP20191396T1
HRP20191396T1 HRP20191396T HRP20191396T1 HR P20191396 T1 HRP20191396 T1 HR P20191396T1 HR P20191396 T HRP20191396 T HR P20191396T HR P20191396 T1 HRP20191396 T1 HR P20191396T1
Authority
HR
Croatia
Prior art keywords
pyrazol
tautomer
stereoisomer
solvate
salt
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Thomas Fuchss
Kai Schiemann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20191396T1 publication Critical patent/HRP20191396T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20191396 2015-04-02 2016-03-31 Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze HRP20191396T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15000968 2015-04-02
EP16717560.3A EP3277681B1 (de) 2015-04-02 2016-03-31 Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
PCT/EP2016/000542 WO2016155884A1 (de) 2015-04-02 2016-03-31 Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren

Publications (1)

Publication Number Publication Date
HRP20191396T1 true HRP20191396T1 (hr) 2019-11-01

Family

ID=52814780

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20191396 HRP20191396T1 (hr) 2015-04-02 2016-03-31 Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze
HRP20210981TT HRP20210981T1 (hr) 2015-04-02 2021-06-23 Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210981TT HRP20210981T1 (hr) 2015-04-02 2021-06-23 Imidazolonil kinolini i njihova uporaba kao inhibitori atm kinaze

Country Status (23)

Country Link
US (5) US10457677B2 (enExample)
EP (3) EP3277681B1 (enExample)
JP (2) JP6791873B2 (enExample)
KR (2) KR102652052B1 (enExample)
CN (3) CN107889488B (enExample)
AU (4) AU2016239270B2 (enExample)
BR (1) BR122019005502B1 (enExample)
DK (2) DK3277681T3 (enExample)
ES (3) ES2880626T3 (enExample)
HR (2) HRP20191396T1 (enExample)
HU (2) HUE054745T2 (enExample)
IL (3) IL254714B (enExample)
LT (2) LT3560924T (enExample)
MX (2) MX376947B (enExample)
PL (2) PL3560924T3 (enExample)
PT (2) PT3560924T (enExample)
RS (2) RS59139B1 (enExample)
RU (1) RU2743343C2 (enExample)
SG (2) SG11201708065QA (enExample)
SI (2) SI3277681T1 (enExample)
TR (1) TR201911244T4 (enExample)
WO (1) WO2016155884A1 (enExample)
ZA (1) ZA201707423B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10457677B2 (en) * 2015-04-02 2019-10-29 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN110312717B (zh) * 2017-02-27 2022-04-12 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CN111587126A (zh) 2018-01-12 2020-08-25 普罗林科斯有限责任公司 组合剂型和用于验证的造影剂毒性最小化方案
AU2019233596A1 (en) * 2018-03-14 2020-10-08 Merck Patent Gmbh Compounds and uses thereof to treat tumors in a subject
EP3904349B1 (en) 2018-04-12 2023-08-23 Bayer Aktiengesellschaft N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}heterocyclyl amide derivatives and similar compounds as pesticides
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
GB201814487D0 (en) * 2018-09-06 2018-10-24 Cycle Pharmaceuticals Ltd Cancer
CN109045042A (zh) * 2018-09-21 2018-12-21 上海交通大学医学院附属上海儿童医学中心 Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用
AU2019348132B2 (en) * 2018-09-30 2022-03-31 Medshine Discovery Inc. Quinolino-pyrrolidin-2-one derivative and application thereof
LT3947375T (lt) 2019-03-27 2024-06-10 Merck Patent Gmbh Imidazolonilchinolino junginiai ir jų terapinis panaudojimas
WO2021022078A1 (en) * 2019-07-30 2021-02-04 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
KR20220095205A (ko) * 2019-11-01 2022-07-06 아레스 트레이딩 에스.아. 암의 치료를 위한 방사선요법과 PD-1, TGFβ 및 ATM의 조합 억제
AU2020398215A1 (en) * 2019-12-04 2022-06-16 Chdi Foundation, Inc. ATM kinase inhibitors and compositions and methods of use thereof
CN115003672A (zh) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
US20230226041A1 (en) * 2020-06-18 2023-07-20 Merck Patent Gmbh Compounds for the treatment of viral infections
WO2021260580A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
CA3190226A1 (en) 2020-09-18 2022-03-24 Merck Patent Gmbh Pharmaceutical preparation
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN115232122B (zh) * 2021-04-23 2024-05-31 石药集团中奇制药技术（石家庄）有限公司 炔类化合物及其制备和应用
CN115716829B (zh) * 2022-11-13 2024-05-31 药康众拓(江苏)医药科技有限公司 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用
KR20250112837A (ko) 2022-11-23 2025-07-24 포워드 테라퓨틱스, 인코포레이티드 TNF-α 활성의 조절제
WO2025157979A1 (en) 2024-01-26 2025-07-31 Merck Patent Gmbh Synthesis route for preparing 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
WO2025212627A1 (en) 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
PL1879893T3 (pl) * 2005-03-21 2010-11-30 Ferrer Int Sposób otrzymywania podstawionych w pozycji 1, związków 1H-imidazo[4,5-c]chinolino-4-aminowych i związki pośrednie
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
BRPI0807893A2 (pt) 2007-02-20 2014-06-17 Novartis Ag Imidazoquinolinas como inibidores duais de lipídio quinase e mtor.
CA2925257C (en) 2008-03-26 2019-04-30 Carlos Garcia-Echeverria 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
CA3000973A1 (en) 2008-06-10 2009-12-17 Abbvie Inc. Tricyclic compounds
CN102170873B (zh) 2008-10-01 2014-07-30 诺华股份有限公司 用于治疗与hedgehog通路有关的病症的smoothened拮抗
US8476294B2 (en) 2009-06-04 2013-07-02 Novartis Ag 1H-imidazo[4,5-c]quinolinone derivatives
JP2012528829A (ja) 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EA201201289A1 (ru) * 2010-03-16 2013-08-30 Мерк Патент Гмбх Морфолинилхиназолины
SG186855A1 (en) * 2010-06-28 2013-02-28 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
WO2012075253A2 (en) 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions
CN103012398B (zh) 2011-09-19 2015-10-14 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
US9879003B2 (en) 2012-04-11 2018-01-30 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
WO2013184621A1 (en) 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
US10457677B2 (en) 2015-04-02 2019-10-29 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors

Also Published As

Publication number Publication date
KR102652052B1 (ko) 2024-03-27
DK3560924T3 (da) 2021-06-28
SI3277681T1 (sl) 2019-09-30
DK3277681T3 (da) 2019-07-29
JP2018510191A (ja) 2018-04-12
US10975075B2 (en) 2021-04-13
US20180072715A1 (en) 2018-03-15
US10457677B2 (en) 2019-10-29
US20210198257A1 (en) 2021-07-01
JP2021046403A (ja) 2021-03-25
RS62082B1 (sr) 2021-08-31
EP3560924A1 (de) 2019-10-30
BR122019005502B1 (pt) 2024-02-27
US20200325137A1 (en) 2020-10-15
IL254714A0 (en) 2017-11-30
HRP20210981T1 (hr) 2021-09-17
KR20240044525A (ko) 2024-04-04
AU2025200385A1 (en) 2025-02-13
EP3868761B1 (de) 2023-03-01
MX390537B (es) 2025-03-20
IL254714B (en) 2020-01-30
AU2022256215A1 (en) 2022-11-24
LT3277681T (lt) 2019-08-12
LT3560924T (lt) 2021-08-25
TR201911244T4 (tr) 2019-08-21
EP3277681B1 (de) 2019-05-08
CN111689963A (zh) 2020-09-22
IL282584B (en) 2021-12-01
NZ774407A (en) 2024-09-27
SI3560924T1 (sl) 2021-08-31
IL271494A (en) 2020-02-27
HUE054745T2 (hu) 2021-09-28
CN107889488A (zh) 2018-04-06
RU2743343C2 (ru) 2021-02-17
ES2741853T3 (es) 2020-02-12
AU2016239270A1 (en) 2017-11-16
US10745399B2 (en) 2020-08-18
ZA201707423B (en) 2021-05-26
PL3277681T3 (pl) 2019-10-31
US20230203034A1 (en) 2023-06-29
ES2880626T3 (es) 2021-11-25
MX2017012613A (es) 2018-01-24
SG11201708065QA (en) 2017-10-30
RU2017138100A3 (enExample) 2019-10-04
RU2017138100A (ru) 2019-05-08
BR112017020941A2 (pt) 2018-07-10
CA2981365A1 (en) 2016-10-06
SG10202002181UA (en) 2020-05-28
IL271494B (en) 2021-05-31
KR20170132323A (ko) 2017-12-01
US20190211013A1 (en) 2019-07-11
CN107889488B (zh) 2020-08-11
JP7111790B2 (ja) 2022-08-02
IL282584A (en) 2021-06-30
WO2016155884A1 (de) 2016-10-06
NZ736641A (en) 2024-09-27
MX376947B (es) 2025-03-07
AU2016239270B2 (en) 2020-03-26
AU2020204241A1 (en) 2020-07-16
PT3560924T (pt) 2021-07-02
EP3560924B1 (de) 2021-03-31
PT3277681T (pt) 2019-08-20
AU2020204241B2 (en) 2022-11-17
RS59139B1 (sr) 2019-09-30
CN111747952A (zh) 2020-10-09
JP6791873B2 (ja) 2020-11-25
US11608338B2 (en) 2023-03-21
PL3560924T3 (pl) 2021-10-11
ES2946507T3 (es) 2023-07-20
EP3868761A1 (de) 2021-08-25
HUE045477T2 (hu) 2019-12-30
MX2020011558A (es) 2022-03-09
EP3277681A1 (de) 2018-02-07

Similar Documents

Publication Publication Date Title
HRP20191396T1 (hr) Imidazolonilkinolini i njihova uporaba kao inhibotora atm kinaze
HRP20240650T1 (hr) Spojevi imidazolonilkinolina i njihova terapeutska upotreba
JP2018510191A5 (enExample)
ES2948949T3 (es) Inhibidores de la interacción menina-MLL
US10500193B2 (en) Combination therapy of HSP90 inhibitors with platinum-containing agents
DK2994467T3 (en) ARYLCHINAZOLIN
HRP20202058T1 (hr) Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje karcinoma
HRP20220886T1 (hr) Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću
JP2014510151A5 (enExample)
UA126177C2 (uk) Похідні 2-амінопіридину або 2-амінопіримідину як інгібітори циклінзалежної кінази
US20180303829A1 (en) Method for treating cancer using a combination of dna damaging agents and atr inhibitors
RU2012153675A (ru) Соединения, пригодные в качестве ингибиторов atr киназы
SI2376485T1 (en) PIRAZINE DERIVATIVES USE AS ATR KINASE INHIBITORS
AR095308A1 (es) Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
SI2833973T1 (en) Compounds useful as inhibitors of ATR kinase and their combination therapy
PE20081379A1 (es) Composiciones farmaceuticas que comprende nilotinib
JP2010533206A5 (enExample)
US10053478B2 (en) COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
US11660301B2 (en) Combination of ATR kinase inhibitors with PARP inhibitors
JP2013213055A5 (enExample)
HRP20201944T1 (hr) Inhibitori kinaze povezane sa tropomiozinom (trk)
JP2013523814A5 (enExample)
RU2704120C2 (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина
CA3214747A1 (en) Combination therapies for the treatment of cancer
BR112014022266A2 (pt) Combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com outros compostos antitumor